217 related articles for article (PubMed ID: 35596704)
21. BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.
Walts AE; Hiroshima K; McGregor SM; Wu D; Husain AN; Marchevsky AM
Diagn Cytopathol; 2016 Jul; 44(7):599-606. PubMed ID: 27121152
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
[TBL] [Abstract][Full Text] [Related]
23. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
[TBL] [Abstract][Full Text] [Related]
24. Evidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology.
Girolami I; Lucenteforte E; Eccher A; Marletta S; Brunelli M; Graziano P; Pisapia P; Malapelle U; Troncone G; Scarpa A; Huang T; Pantanowitz L
Cancer Cytopathol; 2022 Feb; 130(2):96-109. PubMed ID: 34478240
[TBL] [Abstract][Full Text] [Related]
25. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
[TBL] [Abstract][Full Text] [Related]
26. HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion.
Hiroshima K; Wu D; Hamakawa S; Tsuruoka S; Ozaki D; Orikasa H; Hasegawa M; Koh E; Sekine Y; Yonemori Y; Nabeshima K; Tsuji S; Miyagi Y; Imai K
Diagn Cytopathol; 2021 May; 49(5):622-632. PubMed ID: 32441895
[TBL] [Abstract][Full Text] [Related]
27. Inactivation of
Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR
Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962
[TBL] [Abstract][Full Text] [Related]
28. Update on Diagnosing and Reporting Malignant Pleural Mesothelioma.
Savic I; Myers J
Acta Med Acad; 2021 Apr; 50(1):197-208. PubMed ID: 34075773
[TBL] [Abstract][Full Text] [Related]
29. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Berg KB; Dacic S; Miller C; Cheung S; Churg A
Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
31. Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
Pillappa R; Maleszewski JJ; Sukov WR; Bedroske PP; Greipp PT; Boland JM; Yi ES; Peikert T; Aubry MC; Roden AC
Am J Surg Pathol; 2018 Feb; 42(2):256-263. PubMed ID: 29076876
[TBL] [Abstract][Full Text] [Related]
32. Utility of BAP1, p16, and Methylthio-Adenosine Phosphorylase Immunohistochemistry in Cytological and Histological Samples of Pleural Mesotheliomas.
Amacher V; Bode PK; Moch H; Lenggenhager D; Vrugt B
Acta Cytol; 2023; 67(4):444-450. PubMed ID: 36889303
[TBL] [Abstract][Full Text] [Related]
33. The highlights of the 15th international conference of the international mesothelioma interest group - Do molecular concepts challenge the traditional approach to pathological mesothelioma diagnosis?
Klebe S; Galateau Salle F; Bruno R; Brcic L; I Chen-Yost H; Jaurand MC
Lung Cancer; 2022 Jan; 163():1-6. PubMed ID: 34864334
[TBL] [Abstract][Full Text] [Related]
34. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
Churg A; Sheffield BS; Galateau-Salle F
Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
[TBL] [Abstract][Full Text] [Related]
35. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations.
Sheffield BS; Hwang HC; Lee AF; Thompson K; Rodriguez S; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2015 Jul; 39(7):977-82. PubMed ID: 25634745
[TBL] [Abstract][Full Text] [Related]
36. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
Hida T; Matsumoto S; Hamasaki M; Kawahara K; Tsujimura T; Hiroshima K; Kamei T; Taguchi K; Iwasaki A; Oda Y; Honda H; Nabeshima K
Cancer Sci; 2015 Nov; 106(11):1635-41. PubMed ID: 26291840
[TBL] [Abstract][Full Text] [Related]
37. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
[TBL] [Abstract][Full Text] [Related]
38. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma.
Lynggård LA; Panou V; Szejniuk W; Røe OD; Meristoudis C
J Am Soc Cytopathol; 2022; 11(6):385-393. PubMed ID: 35945149
[TBL] [Abstract][Full Text] [Related]
40. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.
Chapel DB; Schulte JJ; Berg K; Churg A; Dacic S; Fitzpatrick C; Galateau-Salle F; Hiroshima K; Krausz T; Le Stang N; McGregor S; Nabeshima K; Husain AN
Mod Pathol; 2020 Feb; 33(2):245-254. PubMed ID: 31231127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]